Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-5.1M $-6.7M $31.2M $-824.0K $-20.2M $-13.6M $-72.0K $254.0K
Depreciation & Amortization $4.4M $4.2M — — $4.9M $5.4M — —
Depreciation $3.8M $3.8M — — $3.5M $5.0M — —
Amortization $535.0K $536.0K — — $388.0K $362.0K — —
Stock-Based Compensation — — — — — — — —
Net Cash from Operating Activities $-11.2M $-16.3M $-682.0K $-4.7M $2.2M $129.0K $226.0K $404.0K
Investing Activities
Capital Expenditures $7.7M $9.0M — — $9.0M $7.4M — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-7.7M $-9.0M — — $-9.0M $-7.4M — —
Financing Activities
Dividends Paid — — $0 $0 $0 $1.3M $0 $0
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-1.8M $44.7M $0 $-18.1M $9.6M $7.2M $0 $0
Net Change in Cash $-20.7M $19.4M $-682.0K $-6.8M $3.2M $49.0K $226.0K $404.0K
Free Cash Flow $-18.9M $-25.3M — — $-6.7M $-7.2M — —
← Newer Page 1 of 8 Older →